Alder BioPharma (ALDR) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alder Biopharm (ALDR) PT Lowered to $27 at BMO Capital
August 9, 2017 8:11 AM EDTBMO Capital lowered its price target on Alder Biopharm (NASDAQ: ALDR) to $27.00 (from $39.00) while maintaining a Outperform rating. Alder reported 2Q EPS of ($1.48), ahead the Streets ($1.62), driven by lower-than-expected R&D expense.
Analyst Matthew Luchini updated the model for 2Q results and adjusted... More
